Key Summary Points {#FPar1}
==================

Use of continuous glucose monitoring (CGM) allows a more complete assessment of overall glycaemic control and supports time-in-range (time a patient is within the glycaemic range of 70 to 180 mg/dL) as a treatment target.At present, there is no CGM literature on the use of CGM to compare the second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100).InRange, a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4 study will collect CGM data over 20 consecutive days from adults with T1D randomised to receive Gla-300 or IDeg-100.The study is designed to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control \[time in range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)\] and coefficient of variation, as assessed using CGM, in adults with T1D.InRange is expected to provide further insight into the utility of CGM as an outcome measure in clinical practice.

Introduction {#Sec1}
============

Around 10% of the total population with diabetes have type 1 diabetes (T1D), and the incidence has been rising steadily during the last 30 years. The Diabetes Control and Complications Trial showed that maintaining glycated haemoglobin (HbA~1c~) levels near 7% is important in reducing the risk of long-term microvascular complications of diabetes \[[@CR1]\]. However, despite advances in technology, hypoglycaemia and the fear it causes remain major barriers to maintaining low glucose levels \[[@CR2], [@CR3]\], and many people with T1D struggle to achieve this recommended glycaemic target \[[@CR4], [@CR5]\]. While there are many reasons why it is difficult to achieve glycaemic targets, having a more stable and reliable basal insulin replacement may contribute to better glycaemic control \[[@CR6]\].

Continuous glucose monitoring (CGM) is a blood glucose measuring technique that has become more common in recent years among people with insulin-treated diabetes \[[@CR7]\]. CGM devices comprise a wearable sensor that uses enzymatic technology to measure glucose in interstitial fluid, a transmitter that wirelessly transmits electrical readings and a receiver that presents the information to the user \[[@CR7]\]. CGM measures glucose levels at intervals of 5--15 min, meaning that data can be used immediately to guide lifestyle and therapeutic adjustments, to help reduce the incidence of hypoglycaemia and to improve glycaemic control overall \[[@CR7]--[@CR9]\]. In addition to monitoring blood glucose, a key metric obtained by CGM is the time within the target glucose range of 70 to 180 mg/dL \[time-in-range (TIR)\] \[[@CR9]\]. TIR profiles can be used to determine the frequency and duration of glycaemic excursions and they can help healthcare professionals to establish personalised glycaemic targets \[[@CR9]\]. The recent consensus report highlighted TIR as the most important actionable metric that can be obtained from CGM \[[@CR9]\].

Insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) are long-acting second-generation basal insulin analogues indicated for the treatment of both T1D and type 2 diabetes (T2D) \[[@CR10], [@CR11]\]. In phase 3 clinical trials, Gla-300 and IDeg-100 once daily have demonstrated better optimised pharmacokinetic (PK) and pharmacodynamic (PD) profiles than the first-generation analogue insulin glargine 100 U/mL, with durations of action lasting over 24 h \[[@CR12]--[@CR14]\]. In a recent noninferiority study of insulin-naïve people with uncontrolled T2D, Gla-300 demonstrated a lower incidence of anytime (24 h) confirmed hypoglycaemia \[≤ 70 mg/dL (≤ 3.9 mmol/L) and \< 54 mg/dL (\< 3.0 mmol/L)\] than those treated with IDeg-100 during the active titration period (weeks 0--12); however, overall improvements in glycaemic control and risk of hypoglycaemia were comparable between the two insulins \[[@CR15]\]. A second head-to-head study conducted in adults with T2D already receiving insulin did not demonstrate superiority for IDeg-100 versus Gla-300 during the maintenance period \[[@CR16]\]. To our knowledge, two small studies have been published that compare Gla-300 and IDeg-100 in people with T2D using CGM, both conducted in Japan \[[@CR17], [@CR18]\]. Yamabe et al. reported no statistically significant difference between the two insulins in any of the CGM metrics assessed, including mean TIR, mean time below range (TBR; both \< 70 and \< 54 mg/dL) and mean coefficient of variation (CV; a CV of \< 36% is taken to represent stable glycaemia \[[@CR18], [@CR19]\]. However, Kawaguchi et al. observed significantly lower anytime (24 h) and nocturnal (0000--0600 hours) CV and TBR with Gla-300 than with IDeg-100 \[[@CR17]\]. Direct comparisons of Gla-300 and IDeg-100 in people with T1D are currently limited to two studies, neither of which used CGM. Interestingly, the results of these two studies contrast with each other: one was a single-centre, randomised, double-blind, crossover, euglycaemic clamp study which showed that once-daily Gla-300 induces less fluctuating steady-state PD profiles and more evenly distributed PK profiles than IDeg-100 \[[@CR13]\], and the other, with a similar crossover design, showed that IDeg-100 provided lower within-day and day-to-day variability in glucose infusion rates than Gla-300 \[[@CR20]\].

The InRange clinical trial will be the first study to use CGM metrics as the primary endpoint to compare the second-generation basal insulin analogues Gla-300 and IDeg-100 in people with T1D. The hypothesis being tested is that Gla-300 is noninferior to IDeg-100 in adults with T1D based on percentage TIR at week 12. Here, we describe the methodology that will be used.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

InRange (study ID no.: LPS14947) is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4 study to compare the glucose values and variability between Gla-300 and IDeg-100 using CGM. This study has been registered on the US National Library of Medicine ClinicalTrials.gov database (NCT04075513).

Study Population {#Sec4}
----------------

Approximately 338 males and females will be recruited from multiple centres following provision of signed informed consent. Eligibility criteria are: 18--70 years of age with T1D; HbA~1c~ ≥ 7% (48 mmol/mol) to ≤ 10% (86 mmol/mol) at screening; previous treatment with multiple daily injections using a basal insulin analogue once daily and rapid-acting insulin analogues for at least 1 year; and treatment with a stable dose of basal/bolus insulin regimen for 30 days prior to screening. Exclusion criteria include: presence of any clinically significant abnormality or adverse event (AE) that may preclude safe completion of the study or constrain efficacy assessment; end-stage renal disease; recent (within 3 months) or planned intravitreal injections, laser treatment or vitrectomy surgery for retinopathy or maculopathy; pregnancy; and bilirubin levels \> 1.5-fold the upper limit of normal or fasting C-peptide levels \> 0.2 nmol/L. Further, participants must not have experienced a change in body weight of ≥ 5 kg within 3 months prior to screening, used an insulin pump within 6 months prior to screening or have received Gla-300 or IDeg-100 as basal insulin within 30 days prior to screening, glucose-lowering drugs other than rapid-acting insulin analogues within 3 months prior to screening or glucocorticoids for \> 10 days within 3 months prior to screening.

Prior to enrolment, the protocol will be reviewed and approved to be in accordance with the ethical standards of the Institutional Review Boards and Independent Ethics Committees of each participating institution in compliance with the Helsinki Declaration. The full list of Institutional Review Boards and Independent Ethics Committees can be found in the Supplementary Material. This study will be conducted in accordance with the Declaration of Helsinki with all relevant amendments, the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, the applicable ICH Good Clinical Practice Guidelines and all applicable laws and regulations.

Randomisation and Study Intervention {#Sec5}
------------------------------------

Participants are to be followed for approximately 18 weeks, which includes 1--2 weeks of screening followed by a 4-week run-in period, a 12-week treatment period and a 2- to 4-day follow-up period (Fig. [1](#Fig1){ref-type="fig"}). During the 4-week run-in period (weeks -- 4 to -- 1), participants undergo stabilisation of their current basal and mealtime insulin treatment and are trained on study-related procedures (weeks -- 4 to -- 3), and baseline CGM values are determined using the blinded CGM device (weeks -- 3 to -- 1). To be eligible for randomisation, a minimum of 10 days (not necessarily consecutive) of useable CGM data must be generated during the run-in period. During the run-in period, participants titrate their basal and mealtime insulin to a fasting self-monitored plasma glucose (SMPG) target of ≥ 70 to \< 100 mg/dL (≥ 3.9 to \< 5.6 mmol/L), and 2-h postprandial SMPG to a target of ≥ 130 to ≤ 180 mg/dL (≥ 7.2 to ≤ 10 mmol/L) \[Electronic Supplementary Material (ESM) Table 1\]. At week 0, participants satisfying the inclusion/exclusion criteria, including CGM handling and compliance with manufacturer's instructions, are randomised 1:1 (stratified by screening HbA~1c~ values of \< 8.0 vs. ≥ 8.0%) to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. The randomised treatment period (weeks 0--12) includes an insulin titration period (weeks 0--8) and a CGM data collection period (over 20 consecutive days during weeks 9--12). During the titration period, doses of Gla-300 or IDeg-100 are titrated at least weekly (but no more often than every 3 days) until participants achieve the target fasting SMPG of ≥ 70 to \< 100 mg/dL (≥ 3.9 to \< 5.6 mmol/L) while avoiding hypoglycaemia episodes (ESM Table 1). Dose adjustments are based on median fasting SMPG values from the last 3 days, including values recorded on the day of titration, as measured by the participant using glucometers and other provided accessories. CGM data is blinded to both the investigators and participants. Participants are followed-up 2--4 days after their last dose to collect post-treatment safety information.Fig. 1Study design. Asterisk indicates telephone calls by investigators to monitor insulin titration weekly between site visits for all participants, unless investigators are attending the study site for sensor replacement. Participant has option to come to site on day −10 and day 74 for sensor replacement. *CGM* Continuous glucose monitoring, *Gla-300* insulin glargine 300 U/mL, *HbA*~*1c*~ glycated haemoglobin, *IDeg-100* insulin degludec 100 U/mL, *MDI* multiple daily injection, *QD* once daily, *R* randomisation, *SMPG* self-monitored plasma glucose, *T1D* type 1 diabetes

Planned Outcomes {#Sec6}
================

Study Objectives {#Sec7}
----------------

The primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 for TIR \[glucose ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)\] and variability in adults with T1D. The secondary aims are to evaluate glycaemic control and other variability parameters in each treatment group at week 12 using CGM in accordance with the International Hypoglycaemia Study Group (IHSG) \[[@CR21]\] and Advanced Technologies and Treatments for Diabetes consensus (ATTD) \[[@CR22]\] criteria for classification of hypoglycaemia, and to compare the treatment safety profiles.

Endpoints {#Sec8}
---------

The primary endpoint is percentage time spent in the glucose range of ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L) at week 12. Secondary endpoints include: glucose total CV and glucose within-day and between-day CV at week 12; change from baseline to week 12 in HbA~1c~ and central laboratory fasting plasma glucose (FPG); percentage time and mean hours per day with glucose \< 70 mg/dL \[anytime and during the night (0000--0559 hours)\] and \> 180 mg/dL; number of participants with AEs; and number of participants with at least one hypoglycaemic event and number of hypoglycaemic events per participant-year from baseline to week 12. Exploratory endpoints include further analysis of glycaemic control and variability parameters at week 12 using CGM; daily insulin doses; patient-reported outcomes in terms of treatment satisfaction, perception of blood glucose control, sleep, and productivity; and 7-point SMPG profiles (further details provided in ESM Information file).

Data Collection {#Sec9}
===============

Continuous Glucose Monitoring {#Sec10}
-----------------------------

Baseline and investigational CGM values are assessed during weeks 0--3 and 9--12, respectively, using the Dexcom G6^®^ Pro CGM System (DexCom, Inc., San Diego, CA, USA). This CGM device records interstitial glucose levels at 5-min intervals for up to 10 continuous days via a subcutaneous sensor inserted into the abdomen at least 8 cm (3 inches) from the insulin injection sites. During each CGM period, participants wear the CGM device for 20 consecutive days to ensure collection of at least 10 days (not necessarily consecutive) of useable data. Useable CGM data for any given day are defined as \> 80% time of records per 24 h and no missing data for ≥ 2 h per 24 h excluding the warm-up time for the sensor after insertion. Participants, investigators and study personnel are blinded to the study CGM data. The data will be uploaded to a separate server that uses vendor software (QuintilesIMS Study Management Suite; IQVIA, Durham, NC, USA) to maintain data anonymity; these data are used to generate a data acceptability report with daily CGM performance. The investigator will use the CGM summary to review each participant's daily performance and to determine the quality of CGM records.

Self-Monitored Plasma Glucose {#Sec11}
-----------------------------

Participants self-monitor plasma glucose levels from week -- 4 using provided Roche Accu-check^®^ glucometers (Roche Diabetes Care, Inc., Mannheim, Germany) and corresponding accessories (lancet, control solutions and test strips). Insulin dose and injection time for basal insulin (prior to randomisation) and during the study treatment period (after randomisation) and all doses of mealtime insulin are documented daily in a provided diary. Pre-injection SMPG is measured 30 min prior to Gla-300 or IDeg-100 before breakfast from day 1 until up-titration has been completed and fasting pre-breakfast SMPG is stable in the target range, and then ≥ 3 times per week. Seven-point SMPG is carried out before (pre-injection after randomisation) and 2 h after all meals, and at bedtime at least once during weeks --1 and 11.

SMPG diary entries are reviewed by the investigators at each visit for episodes of hypoglycaemia and data from glucometers. Weekly telephone calls will be uploaded to site computers at weeks 0, 8 and 12. SMPG data will be used to guide adjustments in basal and mealtime insulin titrations to reach glucose targets.

Glycated Haemoglobin {#Sec12}
--------------------

Glycated haemoglobin levels are assessed at week -- 6/-- 5 (screening), week 0 (randomisation) and week 12. HbA~1c~ is analysed according to a central certified level I National Glycohemoglobin Standardization Program.

Fasting Plasma Glucose {#Sec13}
----------------------

Fasting plasma glucose levels are measured in blood samples taken at week -- 6/-- 5 (screening), week 0 (randomisation) and week 12 at a central laboratory.

Safety Evaluation {#Sec14}
-----------------

All AEs are collected from the time of consent form signing to the end of follow-up to ensure patient safety. An AE is defined as any untoward medical occurrence in a participant that is temporally associated with the use of the study intervention, whether or not it is considered to be related to the study intervention. A serious AE (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalisation or results in persistent disability/incapacity. The investigator is obligated to assess the relationship between study intervention and each occurrence of every AE/SAE and record all AEs leading to discontinuation. All hypoglycaemic episodes are documented in a hypoglycaemia-specific form in the electronic case report form (eCRF), and SMPG diary entries are reviewed by investigators for episodes of hypoglycaemia. The incidence and distribution of hypoglycaemia, proportion of participants experiencing hypoglycaemia and diurnal distribution of hypoglycaemia are analysed according to American Diabetes Association (ADA) criteria for classification of hypoglycaemia (severe, documented symptomatic, asymptomatic, probable and relative) \[[@CR23]\]. Hypoglycaemia fulfilling the seriousness criteria are additionally documented on the SAE form in the eCRF.

Statistical Analysis {#Sec15}
====================

Sample Size {#Sec16}
-----------

The sample size is based on the percentage of time spent in the glucose range of ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L) at week 12, as assessed using the CGM measurements obtained during weeks 10--12. Noninferiority will be tested with a one-sided type I error, and a relative noninferiority margin of 10% is considered. The sample size per treatment group is calculated to provide at least 90% power, assuming a percentage TIR of 56% in the control arm, a common standard deviation (SD) of 14.7% and a non-evaluability rate of 22%.

Analysis of Primary Endpoint {#Sec17}
----------------------------

The percentage of time in the glucose range of ≥ 70 to  ≤ 180 mg/dL (≥ 3.9 to  ≤ 10 mmol/L) at week 12 will be assessed in both arms using 20 days of blinded CGM data during weeks 0--3 and 9--12. An analysis of covariance (ANCOVA) model including the fixed categorical effects of each treatment group and randomisation stratum of screening HbA~1c~ (\< 8.0 vs. ≥ 8.0%), and percentage TIR value as continuous fixed covariate is fitted to provide baseline adjusted least-squares means estimates at week 12 for both treatment groups and the differences between these estimates with corresponding standard errors and 95% confidence intervals (CI). Noninferiority is assessed in the intent-to-treat (ITT) population from the adjusted difference estimate of *m*~1~ -- 0.9 *m*~0~ at week 12 and will be demonstrated if the lower bound of the two-sided 95% CI for this estimate is superior to 0.

Analysis of Secondary Endpoints {#Sec18}
-------------------------------

The CGM endpoints are analysed using the same model described for the primary endpoint using the ITT population. Changes in HbA~1c~ are analysed using an ANCOVA model that includes the fixed categorical effects of Gla-300 and IDeg-100 treatments and the continuous fixed covariate of baseline HbA~1c~. Changes in FPG will be analysed using an ANCOVA model that includes the randomisation stratum of HbA~1c~ at screening (\< 8.0%, ≥ 8.0%), Gla-300 and IDeg-100 treatments and the continuous fixed covariate of baseline FPG. Changes from baseline in the 7-point SMPG profiles (preprandial and 2-h postprandial plasma glucose at all mealtimes, and at bedtime) to week 12 are described by treatment group using the mean and SD. A hierarchical step-down testing procedure will be applied to the primary efficacy endpoint (noninferiority for percentage TIR) and main secondary endpoints \[noninferiority (10% margin) for glucose total CV, and superiority for percentage TIR\] to control for type I error \[[@CR24]\]. For other secondary endpoints and other efficacy variables, no multiplicity adjustments will be made, and any 95% CI and *p* values will be presented for descriptive purposes only.

Strengths and Limitations {#Sec19}
=========================

The strengths of this study are that it is a prospective, multicentre, randomised, active-controlled, parallel-group, open-label, comparative study. The study protocol benefits from requiring minimal blood sampling and the use of CGM devices, both of which have been associated with low risk \[[@CR8], [@CR25], [@CR26]\]. Moreover, the accuracy of CGM has been previously validated in adults with T1D \[[@CR8], [@CR27]\]. Although HbA~1c~ is still considered the key method for evaluating glycaemic control \[[@CR9], [@CR28]\], CGM is likely to become the new gold standard for several reasons \[[@CR29]\]. HbA~1c~ provides a surrogate marker for average blood glucose over the previous few months and, as such, is unable to provide information on acute glycaemic deviations, be it hyper- or hypoglycaemia \[[@CR9]\]. CGM, however, assesses blood glucose either in real-time or at intervals of 5--15 min, thereby facilitating almost immediate surveillance of glycaemic excursions as well as review of daily profiles \[[@CR7], [@CR9], [@CR28]\]. The TIR metric is particularly advantageous because it allows for prompt adjustment of targets specific to each individual \[[@CR9]\]. Nevertheless, there are limitations to CGM technology, including the 5- to 15-min lag between the sensor measuring glucose in interstitial fluid and blood glucose \[[@CR7]\], and accuracy, as assessed by the mean or median absolute relative difference versus reference values obtained in a laboratory, which can be affected by aerobic exercise \[[@CR30]\]. However, within the scope of this study, these limitations will be similarly reflected in both treatment arms.

The open-label nature of the study is an inherent limitation; however, as Gla-300 and IDeg-100 are distinguishable, no attempt is made to blind the randomly assigned study treatment. However, the assessment of outcomes is based on objectively collected data, blinded for CGM (primary and secondary endpoints) and open for SMPG data (secondary endpoint); individual CGM data are inaccessible to the participant, investigator and sponsor to avoid treatment decisions being made based on data for the primary endpoint.

Conclusions {#Sec20}
===========

The InRange trial is the first to use CGM data to assess primary endpoints exploring the similarities and differences of second-generation basal insulin analogues (Gla-300 and IDeg-100) according to the approved labels in adults with T1D. By providing head-to-head comparisons between the two most recently available long-acting basal insulin formulations, InRange should provide comprehensive glucose profiles, as measured by one of the most accurate methods, for participants with T1D receiving Gla-300 and IDeg-100. Additionally, the results should provide further data on the application of TIR in clinical practice.
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